Client news

A&O Shearman advises on Kestra Medical Technologies initial public offering

A&O Shearman advises on Kestra Medical Technologies initial public offering
Published Date
Mar 14 2025
Our capital markets team led by partner Ilir Mujalovic, counsel Roseanne Kross, associates Ilya Mamin and Danish Hyder, and law clerk Jake Schmitz advised the underwriters in connection with the upsized $202 million initial public offering of Kestra Medical Technologies, Ltd.

Kestra is a commercial-stage medical device company that has developed a next generation wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest. The device automatically monitors elevated risk patients and, if needed, delivers a defibrillation shock to return the patient’s heart to normal rhythm.

Related capabilities